Researcher Spotlight: Tayla Heavican-Foral, PhD DANA-FARBER CANCER INSTITUTE DR. OLIVER PRESS MEMORIAL FELLOW HEALTH EQUITY INITIATIVE Despite treatment advances in the lymphoma space, many patients with T-cell lymphomas (TCL) still experience limited response rates, often lasting for short durations, with…
Researcher Spotlight: Patrizia Mondello, MD, PhD MAYO CLINIC, ROCHESTER In most cases, follicular lymphoma (FL) is a slow-growing cancer associated with favorable outcomes. Some patients experience a more aggressive disease course, though, characterized by early relapse and poor outcomes. Crosstalk…
Researcher Spotlight: Elise Chong, MD UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE Health Equity Initiative Chimeric antigen receptor (CAR) T-cell therapy has become a life-saving treatment option for many people with large B-cell lymphoma. Some patients do not respond to…
Researcher Spotlight: Xiaolong (Alan) Zhou, MD NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE The abscopal effect refers to the infrequent ability of radiation therapy (RT) to stimulate antitumor immune responses that result in the shrinkage of tumors outside of RT-targeted sites.…
Researcher Spotlight: Roni Shouval, MD, PhD MEMORIAL SLOAN KETTERING CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies have been a transformative advancement in the treatment of large B-cell lymphomas. However, many patients still experience relapse after CAR T-cell therapy. Using…
Researcher Spotlight: Laurianne Scourzic, PhD JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITYDr. Joseph R. Bertino Memorial Scholar Cancer stem cells have been identified in a variety of tumor types, which contribute to the continuous repopulation of cancer…
Researcher Spotlight: Matthew Klairmont, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE In many cases, follicular lymphoma (FL) is an indolent and treatable B-cell lymphoma, and most patients live a normal lifespan. However, in a subset of patients, the disease can…
Researcher Spotlight: Tayla Foral, PhD DANA-FARBER CANCER INSTITUTE Mature T-cell lymphomas (TCL) are a highlyheterogeneous group of diseases with poor treatment options. Currently, many patients with TCL experience relapsed or refractory disease, and outcomes are generally poor. Dr. Foral’s LRF…
Researcher Spotlight: Robert Albero Gallego, PhD COLUMBIA UNIVERSITY Angioimmunoblastic T-cell lymphomas (AITLs) areaggressive forms of blood cancer and are often resistant to conventional chemotherapy. Certainmutations have been to be very common in AITLs, including mutations in the TET2 and RHOA…
Researcher Spotlight: Owhofasa Agbedia, MBBS, MPH UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Chimeric antigen receptor (CAR)-T cell therapies involve the re-engineering of a patient’s ownimmune cells to help them find and fight cancer cells within the body. This treatment…